Zobrazeno 1 - 10
of 28 050
pro vyhledávání: '"urothelial carcinoma."'
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Renal pelvic urothelial carcinoma with multiple histological variants co-occurs with hydronephrosis and pyelonephritis extremely rarely. The diagnosis of renal pelvic urothelial carcinoma can be complicated by these conditions, le
Externí odkaz:
https://doaj.org/article/0494b2058d5644edafafb230811a334c
Autor:
Irene Testi, Giulia Claire Giudice, Giuseppe Salfi, Martino Pedrani, Sara Merler, Fabio Turco, Luigi Tortola, Ursula Vogl
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 6, Pp 1326-1364 (2024)
Advanced urothelial carcinoma (aUC) has a dismal prognosis, with a 5-year survival rate of approximately 10%. Platinum-based chemotherapy has been the backbone of the first-line treatment of aUC for over 40 years. Only in the last decade, the treatme
Externí odkaz:
https://doaj.org/article/50345d19217b432891d671f63e69aa3f
Autor:
Michael Karl Melzer, Yanchun Ma, Jessica Lindenmayer, Clara Morgenstern, Felix Wezel, Friedemann Zengerling, Cagatay Günes, Nadine Therese Gaisa, Alexander Kleger, Christian Bolenz
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-7 (2024)
Abstract Urothelial carcinoma (UC) of the urinary bladder has significant challenges in treatment due to its diverse genetic landscape and variable response to systemic therapy. In recent years, patient-derived organoids (PDOs) emerged as a novel too
Externí odkaz:
https://doaj.org/article/cfc496e6e02e4966b81c02bc4a642b0d
Autor:
Ji Min Kim, Sanghui Park
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Plasmacytoid urothelial carcinoma (PUC) is a rare and aggressive subtype that often presents at advanced stages with poor prognosis. This study investigated tumor invasion to better understand tumor behavior and potentially to imp
Externí odkaz:
https://doaj.org/article/f1141d133b904b028f87012e5e81e721
Autor:
Chris Ho-Ming Wong, Kang Liu, Hongda Zhao, Kubilay Sabuncu, Rahim Horuz, Selami Albayrak, Maria del Pilar, Laguna Pes, Jean de la Rosette, Jeremy Yuen-Chun Teoh
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Objective This study aims to explore the relationship between pre-existing renal impairment and oncological outcomes in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy (RNU) using data from a multicen
Externí odkaz:
https://doaj.org/article/3fc832f3158346f29190782e3d91b6c5
Autor:
Kira Furlano, Henning Plage, Sebastian Hofbauer, Sarah Weinberger, Bernhard Ralla, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Martina Kluth, Maximilian Lennartz, Niclas C. Blessin, Andreas H. Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Stefan Koch, Nico Adamini, Sarah Minner, Ronald Simon, Guido Sauter, Joachim Weischenfeldt, Tobias Klatte, Thorsten Schlomm, David Horst, Henrik Zecha
Publikováno v:
BJUI Compass, Vol 5, Iss 11, Pp 1081-1089 (2024)
Abstract Objective There is a shortage of established prognostic biomarkers in bladder cancer. One candidate is tumour protein 63 (p63), a transcription factor of the p53 gene family that is expressed in the normal urothelium. Recently proposed RNA e
Externí odkaz:
https://doaj.org/article/858134d5041e486092630ed50c6fad55
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Background The biological significance of cancer-associated fibroblasts (CAFs) in bladder urothelial carcinoma (BUC) warrants further investigation. There is an urgent need to explore the predictive utility of CAF-related genes for prognosis
Externí odkaz:
https://doaj.org/article/ffc3ef39d9914fcfb2fc0092bd3da9ed
Autor:
Mahoro Watanabe, Naoki Kawamorita, Tetsuro Shiraiwa, Tomonori Sato, Takuma Sato, Yoshihide Kawasaki, Shinichi Yamashita, Akiko Ebata, Satoko Sato, Akihiro Ito
Publikováno v:
IJU Case Reports, Vol 7, Iss 6, Pp 448-453 (2024)
Introduction Distant recurrence of non‐muscle invasive bladder cancer is a rare condition that is poorly understood and difficult to detect in follow‐up protocols. Case presentation A 73‐year‐old female with a history of T1N0M0 bladder cancer
Externí odkaz:
https://doaj.org/article/202b92a9236d4409bb62094ce1db6e28
Publikováno v:
BMC Nephrology, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Immune checkpoint inhibitor (ICI) therapy has been widely investigated in urothelial carcinoma; however, the utility of ICI therapy in the treatment of organ transplant recipients with metastatic urothelial carcinoma (mUC) is uncl
Externí odkaz:
https://doaj.org/article/dfc19df11f5447029791b92b330cd80b
Autor:
Jen-Kai Fang, Hsin-Chih Yeh, Hsiang-Ying Lee, Han-Yu Weng, Ta-Yao Tai, Chao-Yuan Huang, Jian-Hua Hong, Chih-Chin Yu, Shu-Yu Wu, Shiu-Dong Chung, Chung-You Tsai, Thomas Y. Hsueh, Allen W. Chiu, Yuan-Hong Jiang, Yu Khun, Lee, I-Hsuan Alan Chen, Jen-Tai Lin, Yung-Tai Chen, Chang-Min Lin, Ian-Seng Cheong, Hsu-Che Huang, Shih-Hsiu Lo, Wei-Yu Lin, Jen-Shu Tseng, Chia-Chang Wu, Shian-Shiang Wang, Yi-Huei Chang, Chao-Hsiang Chang
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Nephroureterectomy with bladder cuff excision is the standard treatment for high-risk upper urinary tract urothelial carcinoma (UTUC). The role of minimally invasive surgery in treating locally advanced UTUC remains controversial.
Externí odkaz:
https://doaj.org/article/85f6696938ec4234b4d653b63291cfd6